bioAffinity Technologies (BIAF) & Its Rivals Head to Head Comparison

bioAffinity Technologies (NASDAQ:BIAF) is one of 39 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its rivals? We will compare bioAffinity Technologies to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares bioAffinity Technologies and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
bioAffinity Technologies	$2.53 million	-$7.94 million	-2.32
bioAffinity Technologies Competitors	$1.56 billion	$101.44 million	8.08

bioAffinity Technologies’ rivals have higher revenue and earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares bioAffinity Technologies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
bioAffinity Technologies Competitors	-249.32%	-18.82%	-11.20%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for bioAffinity Technologies and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0	0	0	0	N/A
bioAffinity Technologies Competitors	50	821	1311	31	2.60

As a group, “Commercial physical research” companies have a potential upside of 15.19%. Given bioAffinity Technologies’ rivals higher probable upside, analysts clearly believe bioAffinity Technologies has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by company insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

bioAffinity Technologies has a beta of 3.15, meaning that its stock price is 215% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ rivals have a beta of 6.00, meaning that their average stock price is 500% more volatile than the S&P 500.

Summary

bioAffinity Technologies rivals beat bioAffinity Technologies on 9 of the 10 factors compared.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.